Close Menu

NEW YORK – CareDx reported after the close of the market on Wednesday that its fourth quarter revenues rose 64 percent year over year, largely in line with the preliminary Q4 revenues the company reported in January.

For the three months ended Dec. 31, 2020, the molecular diagnostics company reported total revenues of $58.6 million, up from $35.8 million during the same period a year earlier and beating the average Wall Street estimate of $55.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News writes that viral genomic surveillance in the US faces systemic issues.

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.